The Implantable Artificial Heart Project
Press Conferences
News Releases
Frequently Asked Questions (FAQ)
Images and Diagrams
The AbioCor Replacement Heart
Frequently Asked Questions (FAQ)
Images and Diagrams
The Researchers
Laman A. Gray, Jr., M.D.
Robert D. Dowling, M.D.

News Releases

July 3, 2001
Linda McGinity Jackson,
Kathy Keadle,
Tess Donovan, Brodeur Worldwide for ABIOMED: 617-587-2981


Louisville, Kentucky - Jewish Hospital and the University of Louisville announced today that the leaders of the Louisville-based AbioCor (pronounced "AB'-EE-O-KOR") clinical and research teams, Drs. Laman A. Gray, Jr. and Robert D. Dowling, performed the world's first implantation of ABIOMED, INC's AbioCor Implantable Replacement Heart on Monday, July 2 in a seven-hour procedure at Jewish Hospital in Louisville, Kentucky. The patient is resting comfortably.

Consistent with the previously announced "quiet period" policy, additional information will be available at a news briefing to be held on Wednesday, July 4 at 10 a.m. (EDT), atop the Rudd Heart and Lung Center on the Jewish Hospital campus, 201 Abraham Flexner Way. ADDITIONAL INFORMATION WILL NOT BE RELEASED PRIOR TO THE NEWS BRIEFING.

The news conference will be up-linked live via satellite coordinates Ku-Band SBS 6, Transponder 15, Horizontal Frequency 12068 MHZ, 74 degrees West. The audio frequency is 6.20/6.80. The signal will be available from 10-11 a.m. (EDT), Wednesday, July 4.


Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced "AB'-EE-O-MED") is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. The Company's first generation AbioCor Implantable Replacement Heart is ready for implantation in selected patients as part of an initial clinical trial conducted under an Investigational Device Exemption (IDE) from the United States Food and Drug Administration (FDA).The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial. ABIOMED currently manufactures and sells the BVS, a heart assist advice for the temporary support of all patients with failing but potentially recoverable hearts.

This Release contains forward-looking statements, including statements regarding the anticipated timing and results of clinical trials for the AbioCor. ABIOMED's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks detailed in the Company's filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

Jewish Hospital is among the top ten cardiac centers in the United States and, along with the University of Louisville, is dedicated to excellence in clinical care, research and education. University of Louisville surgeons at Jewish Hospital have performed many heart care "firsts," including Kentucky's first heart transplant, the world's first heart transplant following the use of a Thoratec left ventricular assist device, the world's first endoscopic saphenous vein harvest and the first ventricular remodeling in the region.

©2001 Jewish Hospital, University of Louisville Health Sciences Center, ABIOMED, Inc.
Jewish Hospital University of Louisville Health Sciences Center